- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Watch Mirum Pharmaceuticals' latest callMirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings CallMirum Pharmaceuticals, Inc. on 6ix
In the deck
Story so far
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
- Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Earlier from Mirum Pharmaceuticals
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
- Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
- Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Later from Mirum Pharmaceuticals
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals